CNP and Parkinson disease: Furthermore, various long-acting analogues of CNP have progressed through clinical trials, for the treatment of rare disorders of endochondral ossification (such as achondroplasia), where it is a promising treatment for short stature [10,41,42], and CNP can act as an anti-inflammatory agent in endothelial cells [43], hepatic fibrosis [44], and is an inflammatory biomarker in Parkinson’s disease [45].